3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Melanoma
34
Carcinoma, Non-Small-Cell Lung
22
Carcinoma, Renal Cell
20
Neoplasm Metastasis
13
Carcinoma, Hepatocellular
10
Brain Neoplasms
8
Lung Neoplasms
7
Skin Neoplasms
6
Neoplasms
6
Squamous Cell Carcinoma of Head and Neck
5
Prostatic Neoplasms
5
Pancreatic Neoplasms
5
Kidney Neoplasms
5
Clear-cell metastatic renal cell carcinoma
5
Carcinoma, Transitional Cell
5
Uveal Melanoma
4
Ovarian Neoplasms
4
Myelodysplastic Syndromes
4
Multiple Myeloma
4
Glioblastoma
4
Carcinoma, Basal Cell
4
Carcinoma
4
Urinary Bladder Neoplasms
3
Urethral Neoplasms
3
Sarcoma
3
Recurrence
3
Mesothelioma
3
Liver Neoplasms
3
Leukemia, Myeloid, Acute
3
Histiocytoma, Malignant Fibrous
3
Interventions
tremelimumab
2
pembrolizumab
2
Nivolumab
2
Carboplatin
2
poly ICLC
1
osimertinib
1
lenvatinib
1
durvalumab
1
cemiplimab
1
balstilimab
1
Vascular Endothelial Growth Factor A
1
Peptides
1
Pemetrexed
1
Paclitaxel
1
Ipilimumab
1
Docetaxel
1
Blood Specimen Collection
1
Antibodies, Bispecific
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Diabetes Mellitus, Insulin-Dependent, 12
×
Ipilimumab
×
90 days
×
Clear all
NCT07000149
2026-03-10
eVOLVE-RCC02
AstraZeneca
Phase 3
Active not recruiting
1,116 enrolled